Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients
STOCKHOLM, – AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Global Life Sciences Conference, March 9-10.
The presentation will be available via s website; www.medivir.com.
More information about the event is available at the organizer’s website: https://hcwevents.com/globalconference/
For additional information, please contact
Yilmaz , CEO
Telephone: +46 8 5468 3100
E-mail: yilmaz.mahshid@medivir.com
Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir is a Swedish biotech company.[1] Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.[2] Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB). The agreement gives SYB the right to register, manufacture and market the product in China.
in brief
r develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medivir/r/medivir-to-present-at-the-h-c–wainwright-global-life-sciences-conference,c3301695
The following files are available for download:
|
https://mb.cision.com/Main/652/3301695/1383543.pdf |
Press release (PDF) |
This article was shared to Prittle Prattle News as a Press Release.
By PR Newswire
